Pfizer halts enrollment in lung cancer trial
Pfizer Inc has halted patient enrollment in a late-stage lung cancer trial of its experimental drug, figitumumab, the drugmaker said on Friday.
Pfizer Inc. said it ended an advanced trial of its experimental lung cancer drug figitumumab after an independent safety committee determined the treatment was unlikely to improve patients' survival.